Short vitrectomy tool for children's eye surgery
Part of Eyes & vision, Genetic & congenital, Heart & circulation clinical trials.
This trial tests a shorter, 18-millimeter tool for vitrectomy surgery in children. It aims to see if this smaller tool is safe and works well for treating various eye problems in kids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are under 18 years old.
- You need vitrectomy surgery (a procedure to remove the gel inside the eye) for conditions like retinopathy of prematurity, eye injury, or other vitreoretinal diseases.
- You can cooperate with detailed eye exams.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special eye scan (OCT) can help guide eye surgery during the operation. It may improve how surgeons see and target the exact eye structures they need to treat.
This study looks at how well surgery called vitrectomy works for people with severe nonproliferative diabetic retinopathy (NPDR), a condition where high blood sugar damages the retina. The trial aims to see if this surgery can improve vision and outcomes.
This trial compares two treatments for early diabetic retinopathy—a condition where high blood sugar damages blood vessels in the eye. Researchers want to see if removing fluid from inside the eye (vitrectomy) works better than laser treatment to prevent vision loss.
This study tests a robotic system to assist eye surgery for certain retina and vitreous conditions, such as bleeding in the eye or a wrinkle on the macula. It aims to see if the robot can safely help improve vision.
This study is looking at how well people do after eye surgery for a condition called myopic foveoschisis, which causes a part of the retina to swell. The study will check if your vision improves after surgery and look for signs of complications.
This trial tests a new treatment for people with a specific type of age-related macular degeneration (AMD) that has not improved after standard anti-VEGF injections. The goal is to see if it can stop vision loss and reduce retinal damage.
Hear when a new Retinal Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.